Diltiazem and Eliquis (Apixaban) Interaction
Diltiazem increases apixaban levels by approximately 40% and is associated with increased bleeding risk, particularly at doses >120 mg/day, but dose reduction of apixaban is NOT routinely recommended unless combined with other risk factors.
Mechanism of Interaction
Diltiazem is a moderate CYP3A4 inhibitor and P-glycoprotein (P-gp) inhibitor 1, 2. Since apixaban is metabolized by CYP3A4 and is a substrate of P-gp, diltiazem increases apixaban exposure by approximately 40% (31% increase in peak concentration, 40% increase in AUC) 3. This is substantially less than the 99% increase seen with strong dual inhibitors like ketoconazole 3.
Clinical Impact on Bleeding Risk
The bleeding risk is real but dose-dependent:
Overall bleeding risk: Diltiazem use with DOACs (including apixaban) increases major bleeding by 38% (OR 1.38) and gastrointestinal bleeding by 19% (OR 1.19) compared to DOAC monotherapy 4
Dose matters significantly:
Renal function doesn't modify risk: The increased bleeding risk occurs regardless of kidney function (CKD vs non-CKD) 7
FDA-Approved Dosing Guidance
The FDA label for Eliquis does NOT require dose reduction with diltiazem 8. Dose reduction is only mandated for combined P-gp AND strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir):
- Reduce apixaban from 5 mg or 10 mg twice daily to 50% of the dose
- Avoid combining diltiazem with patients already on apixaban 2.5 mg twice daily 8
Guideline Recommendations
Current guidelines acknowledge the interaction but provide limited specific guidance:
- The 2016 ACC/AHA/HRS guideline lists apixaban among drugs requiring caution with diltiazem due to CYP3A4/P-gp interactions 1, 2
- The 2018 European Heart Rhythm Association guide classifies diltiazem with apixaban as "yellow" (caution needed, consider dose adjustment if multiple risk factors present) 9
- The 2022 Circulation statement notes diltiazem does not significantly impair apixaban clearance to an appreciable extent compared to verapamil 10
Practical Management Algorithm
When prescribing diltiazem with apixaban:
Assess baseline bleeding risk factors:
- Age ≥80 years
- Weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
- History of bleeding
- Concomitant antiplatelet therapy
Choose diltiazem dose strategically:
- Prefer doses ≤120 mg/day when possible to minimize bleeding risk
- If >120 mg/day needed, ensure close monitoring
Apixaban dosing:
- Continue standard apixaban dosing (5 mg twice daily or 2.5 mg twice daily if dose reduction criteria met per FDA label) 8
- Do NOT empirically reduce apixaban dose solely for diltiazem
- Exception: If patient has ≥2 additional bleeding risk factors, consider alternative rate control agent (metoprolol preferred) 9
Monitoring:
- Educate patient on bleeding signs/symptoms
- Consider more frequent follow-up in first 3 months
- Monitor hemoglobin if any bleeding symptoms
- Apixaban level monitoring may be considered in high-risk patients, though not routinely necessary 11
Alternative Considerations
When to choose metoprolol over diltiazem:
- Multiple bleeding risk factors present
- Prior bleeding event on anticoagulation
- High-dose diltiazem (>120 mg/day) required
- Patient already on reduced-dose apixaban (2.5 mg twice daily)
The evidence consistently shows metoprolol does not increase DOAC levels and serves as the preferred comparator in safety studies 6, 5, 7.
Key Caveats
- The interaction is pharmacokinetic, not pharmacodynamic - it increases drug levels, not anticoagulant effect per se
- Real-world studies show the absolute bleeding risk increase is modest (approximately 5-10 additional events per 1000 person-years) 6, 5
- Stroke risk may actually decrease slightly with the combination (OR 0.83), possibly due to higher anticoagulant levels 4
- Individual patients may have variable responses; the 40% increase in exposure is a population average 11, 3